MedTrace Logo

Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis

NCT00373568 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2010-06-02

No results posted yet for this study

Summary

Miltefosine (longer course) will be used to try to improve the cure rate of mucosal leishmaniasis

Conditions

  • Leishmaniasis

Interventions

DRUG

miltefosine: 2.5 mg/kg/day for 42 days

Sponsors & Collaborators

  • AB Foundation

    lead OTHER

Principal Investigators

  • Jaime Soto, MD · CIBIC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Completion
2007-12-31

Countries

  • Bolivia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00373568 on ClinicalTrials.gov